Shinji Katsura1,2, Takayuki Furuishi1, Haruhisa Ueda1, Etsuo Yonemochi1. 1. School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan. 2. Formulation Research Laboratory, Taiho Pharmaceutical Co., Ltd., 224-2, Ebisuno, Hiraishi, Kawauchi-cho, Tokushima 771-0194, Japan.
Abstract
Using bovine pancreatic ribonuclease A (RNase A) and cholesterol, we synthesized cholesteryl-conjugated ribonuclease A (CHRNase A) to evaluate the influence of a conjugated hydrophobic moiety on protein function. Nuclear magnetic resonance and matrix-assisted laser desorption/ionization time-of-flight spectrometry suggested that one cholesteryl group was conjugated to RNase A. Differential scanning calorimetry indicated that CHRNase A was denatured in the solid state but was folded in phosphate buffer (0.05 mol/L, pH 6.5). CHRNase A resembled RNase A in its secondary structure, but circular dichroism (CD) spectra revealed that the helical content of CHRNase A was decreased and the tertiary structure of CHRNase A differed from that of RNase A. Furthermore, fluorescence measurements, CD spectra, an 8-anilino-1-naphthalenesulfonic acid ammonium salt-based assay, and surface tension measurements suggested that cholesterol was conjugated to a tyrosine residue on the protein surface. The relative activity of CHRNase A to RNase A was 79 ± 7%, and the enzyme activity of CHRNase A by adding β-cyclodextrin (β-CyD) increased to 129 ± 7%. Therefore, we considered that the cholesteryl group interacted with substrate (cytidine 2'3'-cyclic monophosphate monosodium salt) to inhibit the enzyme reaction. Finally, the environment around tyrosine residues in CHRNase A in dimethyl sulfoxide was similar to that of native RNase A in phosphate buffer (0.05 mol/L, pH 6.5). These results suggest that cholesterol conjugation to RNase A altered RNase A functionality, including improvement of RNase A resistance to dimethyl sulfoxide and modulation of the ability of β-CyD to control RNase A enzymatic activity.
Using bovine pancreatic ribonuclease A (RNase A) and cholesterol, we synthesized cholesteryl-conjugated ribonuclease A (CHRNase A) to evaluate the influence of a conjugated hydrophobic moiety on protein function. Nuclear magnetic resonance and matrix-assisted laser desorption/ionization time-of-flight spectrometry suggested that one cholesteryl group was conjugated to RNase A. Differential scanning calorimetry indicated that CHRNase A was denatured in the solid state but was folded in phosphate buffer (0.05 mol/L, pH 6.5). CHRNase A resembled RNase A in its secondary structure, but circular dichroism (CD) spectra revealed that the helical content of CHRNase A was decreased and the tertiary structure of CHRNase A differed from that of RNase A. Furthermore, fluorescence measurements, CD spectra, an 8-anilino-1-naphthalenesulfonic acid ammonium salt-based assay, and surface tension measurements suggested that cholesterol was conjugated to a tyrosine residue on the protein surface. The relative activity of CHRNase A to RNase A was 79 ± 7%, and the enzyme activity of CHRNase A by adding β-cyclodextrin (β-CyD) increased to 129 ± 7%. Therefore, we considered that the cholesteryl group interacted with substrate (cytidine 2'3'-cyclic monophosphate monosodium salt) to inhibit the enzyme reaction. Finally, the environment around tyrosine residues in CHRNase A in dimethyl sulfoxide was similar to that of native RNase A in phosphate buffer (0.05 mol/L, pH 6.5). These results suggest that cholesterol conjugation to RNase A altered RNase A functionality, including improvement of RNase A resistance to dimethyl sulfoxide and modulation of the ability of β-CyD to control RNase A enzymatic activity.
Recently,
protein chemical modification (PCM) has emerged as a
major technique in the chemical biology field and has found applications
in industrial and pharmaceutical areas. The goal of PCM is to enhance
the functionality of proteins by increasing their structural and functional
diversity.[1,2] This technique has also been used in the
development of new drugs, including antibody–drug conjugates.[3−5] Proteins can be chemically modified in several ways, including through
conjugation to polyethylene glycol (PEG), which has proved useful
in clinical applications. PEG conjugation not only improves the stability
and solubility of proteins but also increases their retention time
in the body.[6−9] Many proteins are modified with hydrophilic groups; for example,
polysaccharides may be conjugated to proteins in this manner, which
improves their thermal stability against stress conditions.[10−12] Although most proteins are modified with hydrophilic groups, some
studies have introduced modifications with hydrophobic groups.[13,14]In natively structured proteins, hydrophobic residues are
burried;[15,16] however, protein denaturation, induced by
physical stress, heat,
or chemical exposure, allows these residues to become exposed.[13,17−19] Aggregation of proteins is mediated by hydrophobic
interactions between the newly exposed hydrophobic residues of denatured
proteins.[20,21] In addition, protein aggregation caused
by denaturation can alter the biological activity of proteins, including
changing their immunogenicity. Thus, protein aggregation is instead
a factor to be avoided in the design and development of biological
pharmaceuticals and must be appropriately controlled.[22,23] Consequently, very few studies have explored the use of hydrophobic
groups and their chemical modifications in the field of PCM. Typically,
organic solvents are required for the conjugation of hydrophobic groups,
resulting in protein denaturation. Furthermore, hydrophobic interactions
between modified hydrophobic groups and hydrophobic residues, which
were exposed by protein denaturation, could drive protein aggregation.However, some studies have reported the successful conjugation
of hydrophobic groups to water-soluble polymers, such as cholesterol-bearing
pullulan (CHP)[24] and cholesterol-bearing
poly-l-lysine (CHPLL).[25] These
cholesterol-based materials have been reported to self-assemble into
nanogels in an aqueous solution via the hydrophobic interactions between
the conjugated cholesteryl groups. Functionally, CHP mimics natural
molecular chaperones,[26,27] and because of its ability to
trap hydrophobic molecules, it has wide applications in drug delivery.[28] Furthermore, the α-helical structures
of CHPLL are controlled by host–guest interactions between
cholesterol and cyclodextrin.[25] Therefore,
chemical modification of a hydrophobic group to water-soluble polymers
may not only help enhance the existing functions of polymers but also
introduce novel functions due to the formation of new intermolecular/intramolecular
hydrophobic interactions.Therefore, if hydrophobic modifications
can be conducted to keep
a protein activity, novel functions would be introduced by hydrophobic
modification. Furthermore, we consider that the hydrophobic interactions
associated with conjugated hydrophobic residues, in conjunction with
the existing hydrophobic residues in a molecule, could accelerate
the refolding of proteins.In the present study, we used bovine
pancreatic ribonuclease A
(RNase A) as a model protein for conjugation with the hydrophobic
group cholesterol and synthesized a novel cholesteryl-conjugated RNase
A (CHRNase A). RNase A is a 124 amino acid, single-chain protein (molecular
weight, 13.7 kDa) that catalyzes the cleavage of phosphodiester bonds
in various types of single-stranded RNA.[29−32] RNase A is an extensively studied
and homogeneous enzyme, and proteins with structural homology to RNase
A belong to the RNase A superfamily.[33] Some
RNases in this superfamily exhibit anti-HIV-1 activity and induce
cytotoxic effects in tumor cells.[33] Notably,
RNase mimics that can irreversibly cleave or otherwise elicit damage
to targeted mRNA transcripts represent a particularly promising therapeutic
approach to combat various diseases.[34] Cholesterol
has been widely reported to improve the hydrophobicity, biocompatibility,
and biodegradability of materials and is therefore frequently used
in drug-delivery systems. Cholesterol has been found to be more efficient
than high-molecular-weight polymers in this regard, as these polymers
tend to gradually degrade.[35] Cholesterol
is a vital building block for the structural integrity of cell membranes
and maintains the fluidity and permeability of membranes. It is also
important for intracellular transport and mediates signal transduction
and cellular trafficking.[36−38]Antisense oligonucleotides
(ASOs) interacts with a target RNA.
Michael et al. reported that cholesterolASO conjugates showed a fivefold
enhancement of ASO potency in the muscles of rodents compared with
unconjugated ASOs.[39] Therefore, cholesterol
conjugation to RNase A may affect the activity of the enzyme. We also
conducted a structural characterization of CHRNase A using nuclear
magnetic resonance (NMR) spectroscopy, matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS), fluorescence, differential
scanning calorimetry (DSC), and circular dichroism (CD) measurements.
We also calculated the surface hydrophobicity of CHRNase A via a fluorescence
assay using 8-anilino-1-naphthalenesulfonic acid ammonium salt (ANS)
and surface tension. Furthermore, the enzyme activity was evaluated
using cytidine 2′3′-cyclic monophosphate monosodium
salt (cCMP) as a substrate. Finally, using fluorescence measurements,
we investigated the environment of aromatic amino acids in dimethyl
sulfoxide (DMSO). CHRNase A exhibited novel functions such as control
of enzyme activity by addition of β-cyclodextrin (β-CyD)
and resistance to DMSO. The results suggested that proteins can be
imbued with novel functions by modification with hydrophobic moieties.
Results and Discussion
Confirmation of Cholesterol
Conjugation to
RNase A and the Number of Conjugated Cholesteryl Groups
NMR Spectroscopy
We first used
NMR to confirm that cholesterol was successfully conjugated to RNase
A. 1H NMR spectra of RNase A alone, CHRNase A, and a physical
mixture of RNase A and cholesterol (RNase A [mol]/cholesterol [mol]
= 1/12) in DMSO-d6 were acquired. Figure shows that the 1H NMR spectrum of CHRNase A differed from that of the physical
mixture. A 1H signal from the cholesteryl group in CHP
(0.6–2.4 ppm) was observed in DMSO-d6.[24] Therefore, the 1H signal
in the CHRNase A spectrum at approximately 2 ppm likely corresponds
to the cholesteryl group, as this 1H signal was not present
in the spectra of either RNase A or the physical mixture. Cholesterol
was conjugated to RNase A via the carbonyl carbon (C=O) of N,N′-carbonyldiimidazole (CDI). Figure shows the 13C NMR spectra of RNase A and CHRNase A in DMSO-d6. The 30 and 200 ppm signals in the 13C NMR
spectrum of CHRNase A correspond to the carbon in the cholesteryl
group and the C=O group that connects RNase A to cholesterol,
as these signals were not seen for RNase A. In addition, a 1H–13C heteronuclear multiple-quantum correlation
(HMQC) NMR spectrum demonstrated a correlation between the 1H signal at approximately 2.0 ppm and the 13C signal at
approximately 30 ppm (Figure S1). We thus
concluded that we successfully synthesized RNase A conjugated to cholesterol.
Figure 1
1H NMR spectra of the indicated samples in DMSO-d6 at 25 °C. (a) RNase A, (b) CHRNase A,
and (c) physical mixture of RNase A and cholesterol. The red circle
shows 1H signal from the cholesteryl group. RNase A and
CHRNase A concentration: 21.4 mg/mL. Physical mixture of RNase A and
cholesterol (RNase A [mol]/cholesterol [mol] = 1/12) concentration:
21.4 mg/mL.
Figure 2
13C NMR spectra of RNase A and CHRNase
A in DMSO-d6 at 25 °C. (a) RNase
A and (b) CHRNase
A. The red circles at approximately 30 and 200 ppm show 13C signal from the cholesteryl group and carbonyl group connecting
RNase A and cholesteryl group. RNase A and CHRNase A concentration:
21.4 mg/mL.
1H NMR spectra of the indicated samples in DMSO-d6 at 25 °C. (a) RNase A, (b) CHRNase A,
and (c) physical mixture of RNase A and cholesterol. The red circle
shows 1H signal from the cholesteryl group. RNase A and
CHRNase A concentration: 21.4 mg/mL. Physical mixture of RNase A and
cholesterol (RNase A [mol]/cholesterol [mol] = 1/12) concentration:
21.4 mg/mL.13C NMR spectra of RNase A and CHRNase
A in DMSO-d6 at 25 °C. (a) RNase
A and (b) CHRNase
A. The red circles at approximately 30 and 200 ppm show 13C signal from the cholesteryl group and carbonyl group connecting
RNase A and cholesteryl group. RNase A and CHRNase A concentration:
21.4 mg/mL.Furthermore, we obtained the nuclear
Overhauser effect (NOE) difference
spectrum of CHRNase A through radio frequency irradiation of the 1H signal at approximately 2 ppm, corresponding to the signal
of the cholesteryl group in CHRNase A (Figure S2). NOE measurement provides information about spatial proximity
of protons in a molecule. If the spatial distance between the cholesteryl
group and amino acids was close, negative signals would be observed
in the NOE difference spectra. Conversely, if the spatial distance
was far, signals would not be observed. The results suggested that
the spatial distance of conjugated cholesteryl group is close to many
amino acid groups in DMSO.
MALDI-TOF MS
The NMR results suggested
that cholesterol was conjugated to RNase A in our CHRNase A sample.
However, we could not determine the number of conjugated cholesteryl
groups in CHRNase A using this technique. Therefore, we next applied
MALDI-TOF MS to confirm the number of conjugated cholesteryl groups
in CHRNase A. The MALDI-TOF MS spectra of RNase A and CHRNase A, with
α-cyano-4-hydroxycinnamic acid (CHCA) used as the matrix, were
similar (Figure S3a). Therefore, the conjugated
cholesteryl group may have been cleaved by an analytical process,
such as sample preparation or irradiation by the laser during MALDI-TOF
MS. Consequently, we conducted MALDI-TOF MS using another matrix (sinapinic
acid, SA). Upon using SA as the matrix, the m/z of CHRNase A increased by approximately 400 Da compared
with that of RNase A (Figure S3b), suggesting
that the number of cholesteryl groups conjugated to RNase A was one.
Structural Characterization of CHRNase A
Evaluation of Protein State in Solid and
Buffer Solution by DSC
Proteins that are denatured because
of thermal stress undergo conformational collapse. DSC measures the
thermal stability of proteins by detecting changes in their conformation.
The endothermic peak observed in DSC is indicative of a cooperative
structural transition, which classically corresponds to a native-denatured
transition and occurs in both solid[40−42] and aqueous solutions.[43−47] Furthermore, there is an increase in hydrophobic hydration when
a protein transitions from the native (folded) state to the denatured
(unfolded) state. Therefore, to evaluate the state of hydrophobic
residues in CHRNase A, we measured the DSC in both solid state and
phosphate buffer (0.05 mol/L, pH 6.5). Phosphate buffer was composed
of Na2HPO4 and KH2PO4.Figure a,b shows
the DSC thermograms for RNase A and CHRNase A in the solid and buffer
solutions, respectively. In the solid state (Figure a), an endothermic peak was observed for
RNase A and for the physical mixture of RNase A and cholesterol. The
maximum peak of the endothermic
point (Tm) of RNase A was observed at 110 °C,
and that of the physical mixture was observed at 113 and 138 °C.
Conversely, an endothermic peak for CHRNase A was not observed within
the measurement range. Both acetone and DMSO were used during the
synthesis of CHRNase A, which may have resulted in denaturation of
the protein and hence the absence of the endothermic peak. We also
evaluated whether CHRNase A in the solid state was denatured using
other methods. As Fourier transform infrared (FT-IR) spectroscopy
can be used to evaluate protein conformation using solid samples,
using the potassium bromide (KBr) pellet method, we applied FT-IR
measurements of RNase A and CHRNase A (Figure S4). In FT-IR measurements of proteins, amide band I (near
1650 cm–1) indicates C=O stretching and amide
band II (near 1550 cm–1) indicates N–H bending
and C–N stretching.[48,49] The intensity of the
amide II band in proteins disappears upon unfolding, whereas the amide
I band remains unchanged.[50] Therefore,
we confirmed whether CHRNase A was unfolded by evaluating the ratio
of transmittance (intensity) for amide II to amide I (Figure S4) and found that the ratios in RNase
A and CHRNase A were 2.1 and 1.4, respectively. In agreement with
the DSC measurements, these results suggested that CHRNase A was unfolded
in the solid state.
Figure 3
DSC thermograms for the indicated samples in the solid
state (a)
and phosphate buffer (0.05 mol/L, pH 6.5) (b). Solid state: weight
of RNase A, CHRNase A, and physical mixture of RNase A and cholesterol
(RNase A [mol]/cholesterol [mol] = 1/12): 5 mg. Buffer solution: RNase
A and CHRNase A concentration: 30 mg/mL.
DSC thermograms for the indicated samples in the solid
state (a)
and phosphate buffer (0.05 mol/L, pH 6.5) (b). Solid state: weight
of RNase A, CHRNase A, and physical mixture of RNase A and cholesterol
(RNase A [mol]/cholesterol [mol] = 1/12): 5 mg. Buffer solution: RNase
A and CHRNase A concentration: 30 mg/mL.Figure b shows
that in buffer solution, the Tm’s of RNase
A and CHRNase A were detected at 67 °C, indicating that CHRNase
A was folded in buffer solution. Cholesterol-bearing polysaccharides
and peptides, such as CHP[24] and CHPLL,[25] were previously shown to form hydrogel nanoparticles,
suggesting that the conjugated cholesteryl group could affect the
folding of CHRNase A in buffer solution. These results suggest that
CHRNase A was folded in buffer solution, although it was denatured
in the solid state.
Evaluation of the Secondary
and Tertiary
Structures by CD Spectroscopy
The results of the DSC and
FT-IR indicated that CHRNase A was denatured in the solid state but
folded in phosphate buffer (0.05 mol/L, pH 6.5). We measured CD to
evaluate the secondary and tertiary structures of CHRNase A, which
may have been affected by hydrophobic interactions mediated by the
cholesteryl group.[51−53]RNase A (type α + β) comprised
both α-helix and β-sheet secondary structures, with a
greater percentage of the composition made up of β-sheets than
that of α-helices.[54]Figure a shows the CD spectra of RNase
A and CHRNase A in the far-ultraviolet (UV) (200–250 nm) region,
providing information on protein secondary structure. Although the
CD spectrum of CHRNase A was similar to that of RNase A, indicating
that CHRNase A still exhibited a secondary structure comprising α-helices
and β-sheets, the absolute value at 222 nm was lower than that
of RNase A. As the ellipticity at 222 nm in CD spectra is correlated
with a protein’s α-helical content,[51−53] this therefore
indicates that the α-helical content in CHRNase A was lower
than that of RNase A.
Figure 4
CD spectra of RNase A and CHRNase A in phosphate buffer
(0.05 mol/L,
pH 6.5) at 25 °C. (a) Far-UV (200–250 nm) region and (b)
near-UV (250–320 nm) region. RNase A and CHRNase A concentration:
0.5 mg/mL.
CD spectra of RNase A and CHRNase A in phosphate buffer
(0.05 mol/L,
pH 6.5) at 25 °C. (a) Far-UV (200–250 nm) region and (b)
near-UV (250–320 nm) region. RNase A and CHRNase A concentration:
0.5 mg/mL.The CD spectrum in the near-UV
(250–320 nm) region reflects
the environment of aromatic residues and provides information about
the protein tertiary structure. Figure b shows the CD spectra of RNase A and CHRNase A in
the near-UV region. The signal in the region around 275 nm, which
arises from tyrosine (Tyr) residues, differed between CHRNase A and
RNase A. RNase A has six Tyr residues: three are buried in the protein
interior (i.e., Tyr25, Tyr92, and Tyr97) and three were partly exposed
(i.e., Tyr73, Tyr76, and Tyr115), where the hydroxyl groups of the
exposed Tyr interact with solvent.[47,54] It has previously
been shown that the intensity around 275 nm decreases because of the
unfolding of RNase A by thermal stress.[31,47] Therefore,
the change in the CD spectrum of CHRNase A around 275 nm was likely
derived from a change in the environment of the Tyr residues, such
as cholesterol conjugation to Tyr or exposure of Tyr to the protein
surface.Altogether, the CD and DSC analyses suggest that CHRNase
A existed
in the folded state in buffer solution. Although the secondary structure
of CHRNase A was similar to that of RNase A, its tertiary structure
differed, which may have been induced by cholesterol conjugation to
RNase A.
Evaluation of the Environment
around Aromatic
Residues and Surface Hydrophobicity Using Fluorescence Spectroscopy
Absorption and fluorescence emission at 280 nm are indicative of
the environment around aromatic residues in proteins, especially tryptophan
(Trp) and Tyr, which is associated with their high quantum yield and
extinction coefficient. Therefore, we applied fluorescence measurements
with excitation at 280 nm to investigate the environment around aromatic
residues in CHRNase A.[55−57]The fluorescence emission spectra of proteins
shift to short wavelengths (blue shift) when the environment around
aromatic residues is hydrophobic,[56−59] whereas there is a shift to longer
wavelengths (red shift) when the environment is hydrophilic.[56−59] Thus, these changes indicate whether a protein is in the native
or denatured state. Also, conjugation of chemical group may promote
environmental shifts around aromatic residues.Figure a depicts
the fluorescence emission spectra of RNase A and CHRNase A. RNase
A has six Tyr and three phenylalanine (Phe) residues but no Trp residues.[29,30] The maximum fluorescence emission spectra (λmax) for both RNase A and CHRNase A occurred at 306 nm, attributed to
Tyr (Tyr λmax = 305 nm), and the intensity of the
CHRNase A spectrum was similar to that of RNase A. These results indicated
that the environment around buried and exposed Tyr residues in CHRNase
A was highly similar to that of RNase A. Fluorescence emission spectrum
excited at 280 nm is attributed to the emission of the aromatic ring
in aromatic amino acid residues.
Figure 5
Fluorescence measurements of each RNase
A and ANS in phosphate
buffer (0.05 mol/L, pH 6.5) at 25 °C. (a) Fluorescence emission
spectra of RNase A and CHRNase A in 0.05 mol/L phosphate buffer (pH
6.5) at 25 °C. (1) RNase A and (2) CHRNase A. RNase A and CHRNase
A concentration: 0.5 mg/mL. Excitation wavelength: 280 nm. (b) Fluorescence
emission spectra of ANS and ANS with RNase A or CHRNase A in 0.05
mol/L phosphate buffer (pH 6.5) at 25 °C. (1) ANS, (2) ANS with
RNase A, and (3) ANS with CHRNase A. ANS concentration: 1.0 ×
10–4 mol/L; RNase A and CHRNase A concentration:
0.5 mg/mL. Excitation wavelength: 365 nm.
Fluorescence measurements of each RNase
A and ANS in phosphate
buffer (0.05 mol/L, pH 6.5) at 25 °C. (a) Fluorescence emission
spectra of RNase A and CHRNase A in 0.05 mol/L phosphate buffer (pH
6.5) at 25 °C. (1) RNase A and (2) CHRNase A. RNase A and CHRNase
A concentration: 0.5 mg/mL. Excitation wavelength: 280 nm. (b) Fluorescence
emission spectra of ANS and ANS with RNase A or CHRNase A in 0.05
mol/L phosphate buffer (pH 6.5) at 25 °C. (1) ANS, (2) ANS with
RNase A, and (3) ANS with CHRNase A. ANS concentration: 1.0 ×
10–4 mol/L; RNase A and CHRNase A concentration:
0.5 mg/mL. Excitation wavelength: 365 nm.The CD spectrum of approximately 275 nm reflects the environment
of Tyr residues, and the y-axis of the CD spectrum shows ellipticity.
Ellipticity suggests the different extinction coefficient or absorbance
of left and right circularly polarized light. If Tyr residues were
exposed to the surface, λmax of CHRNase A reveals
a longer shift (red shift) and the intensity changes. However, these
changes were not observed in CHRNase A. Thus, we assumed that the
alteration of CD spectrum of approximately 275 nm may have been induced
by the conjugation of cholesteryl to the Tyr residue.Buried
hydrophobic residues in RNase A could have been exposed
to the protein surface during the synthesis process and/or cholesterol
conjugation. Additionally, because cholesterol is highly hydrophobic,
its conjugation to RNase A could have increased the surface hydrophobicity
of the protein. Therefore, we applied fluorescence measurements at
365 nm using ANS to evaluate the hydrophobicity on the surface of
CHRNase A. ANS is a fluorescent probe that binds to hydrophobic regions
on protein surfaces with high affinity and has therefore been used
for the characterization of protein binding sites and the study of
folding pathways.[47,60−63]The λmax value of ANS shifts to shorter wavelengths
(blue shift) when it transits from a polar to a nonpolar environment,
which also increases its fluorescence intensity. Figure b depicts the fluorescence
emission spectra of ANS and ANS with RNase A or CHRNase A. The λmax value and intensity for ANS in the presence of RNase A
differed slightly from those for ANS alone. Conversely, both values
for ANS with CHRNase A were significantly altered compared with those
for ANS alone and ANS with RNase A. These results suggest that the
hydrophobic regions on the surface of CHRNase A were higher than the
hydrophobic regions on the surface of RNase A, which may correspond
to an increased exposure of hydrophobic residues on the protein’s
surface because of the synthesis process and/or cholesterol conjugation.
However, on the basis of the fluorescence and CD measurements, we
could not determine whether the cholesteryl group was located on the
interior or surface of the protein.The surface tension of proteins
is decreased by denaturation, as
hydrophobic residues typically buried in the interior of proteins
are exposed to the surface.[64,65] Therefore, we measured
the surface tension of RNase A and CHRNase A in phosphate buffer (0.05
mol/L, pH 6.5) and found that both RNase A and CHRNase A exhibited
surface tensions of 59 mN/m. This suggests that the extent of hydrophobic
residue exposure in CHRNase A was similar to that of RNase A. Thus,
the apparent increase in hydrophobicity of CHRNase A likely corresponded
to the presence of the cholesteryl group on the protein surface in
buffer solution, indicating that the conjugated cholesteryl group
was located on the surface of the protein. However, if this were the
case, the cholesteryl group could induce protein aggregation. Therefore,
we analyzed the particle size of RNase A and CHRNase A at a concentration
of 1.0 mg/mL. The particle size for both RNase A and CHRNase A was
approximately 119 nm, which indicated that the cholesteryl group was
unlikely to drive the aggregation of the modified protein.
Enzyme Activity of CHRNase A
Relative
Activity and Enzyme Kinetic Constants
of CHRNase A
The changes we observed in the conformation
and hydrophobicity on the protein surface of CHRNase A may have affected
its enzyme activity. Therefore, using cCMP as a substrate and monitoring
turbidity at 286 nm, we evaluated the enzyme activity of RNase A and
CHRNase A.[32,66] This demonstrated that the relative
activity of CHRNase A to RNase A was 79 ± 7%, implying that the
enzyme activity of CHRNase A decreased compared with that of RNase
A. We then measured the enzyme activity of RNase A and CHRNase A,
again using cCMP (0.02–0.1 mg/mL), at 25 °C (Figure S5), and calculated the Michaelis constant
(Km) and the maximum rate (Vmax) from the Lineweaver–Burk plots (Table S1). The Km value of CHRNase A was higher than that of RNase A, although the Vmax value of CHRNase A was almost the same as
that of RNase A. The Km value indicates
the affinity of an enzyme for a substrate, where a larger Km suggests that the enzyme substrate complex
forms at higher concentrations. As previously indicated, Ostergaard
et al. reported that cholesterolASO conjugates showed a 5-fold enhancement
of ASO potency in rodents relative to unconjugated ASOs.[39] RNA comprised cytidine monophosphate, and cCMP
is a kind of structural isomer. Furthermore, ASOs interact with their
target RNA. Therefore, we suggest that larger Km of CHRNase A was conformational change induced by cholesterol
conjugation and interaction between conjugated cholesteryl group and
cCMP.
Effect of the Addition of β-CyD to
CHRNase A on Enzyme Activity
β-CyD can trap cholesterol
in a hydrophobic cavity because of its high binding constant with
cholesterol.[67] We expected the inhibition
by interaction with cholesteryl group and cCMP to be eliminated with
the addition of β-CyD if the decrease of the affinity to cCMP
was derived from the conjugated cholesteryl group. Therefore, we evaluated
the enzyme activity of CHRNase A before and after adding β-CyD
using cCMP.The relative enzyme activity of CHRNase A with β-CyD
to CHRNase A without β-CyD was 129 ± 7% (estimated relative
activity to RNase A: about 100%). This suggested that the inhibition
by interaction with cholesteryl group and cCMP could be eliminated
by adding β-CyD. However, this experiment could not reveal the
mechanism by which the enzyme activity of CHRNase A was altered with
the addition of β-CyD. For example, β-CyD could have induced
a conformational change of protein by trapping the cholesteryl group.
Therefore, we conducted CD measurements of CHRNase A before and after
adding β-CyD in the far- and near-UV regions (Figure S6). The results suggested that a conformational change
did not occur after adding β-CyD. Thus, we assumed that the
inhibition of enzyme reaction for CHRNase A occurred because of an
interaction between the cholesteryl group and cCMP and the inhibition
could be eliminated by binding of the cholesteryl group to the hydrophobic
cavity in β-CyD (Figure ). This indicates that the enzymatic activity in CHRNase A
can be controlled in the manner of an allosteric enzyme.
Figure 6
Schematic illustration
of the possible enzymatic reaction of CHRNase
A.
Schematic illustration
of the possible enzymatic reaction of CHRNase
A.
Evaluation
of the Environment of Tyr Residues
in DMSO
DMSO is used as protein denaturant at high concentrations[17,68] and can induce conformational changes in proteins by binding to
newly exposed hydrophobic and aromatic side chains upon protein unfolding.[17]We used 100% DMSO as a solvent in the
synthesis of CHRNase A, and acetone was used to obtain the powdered
product, which induced the denaturation of CHRNase A in the solid
state. However, we observed that CHRNase A was folded in phosphate
buffer (0.05 mol/L, pH 6.5). This suggested that hydrophobic interactions
with the conjugated cholesteryl group may promote the folding of CHRNase
A in organic solvents such as DMSO. Although the NOE result (Figure S3) indicated that the conjugated cholesteryl
group is located near amino acid residues in the presence of 100%
DMSO, it did not elucidate whether CHRNase A is in the native state
in DMSO.As fluorescence measurements can evaluate the environment
surrounding
Tyr residues and indicate the folding state of proteins, we applied
fluorescence measurements of CHRNase A in DMSO at 25 °C. Figure shows the fluorescence
emission spectra of RNase A and CHRNase A in phosphate buffer (in
0.05 mol/L, pH 6.5) and 100% DMSO. A red shift of λmax and an increase in the fluorescence intensity imply that aromatic
amino acids are exposed to the protein surface.[56−59] The λmax of
RNase A in DMSO (310 nm) showed a red shift compared with that of
RNase A in 0.05 mol/L phosphate buffer (pH 6.5, 307 nm), with a concomitant
increase in fluorescence. Conversely, the λmax of
CHRNase A in DMSO (307 nm) was highly similar to that of the protein
in 0.05 mol/L phosphate buffer (pH 6.5). However, the intensity of
CHRNase A in DMSO was decreased compared with that of CHRNase A in
0.05 mol/L phosphate buffer (pH 6.5). The environment of Tyr in CHRNase
A in both buffer and DMSO was similar to that of native RNase A, but
RNase A was denatured in 100% DMSO. Thus, it was inferred that CHRNase
A could form a folded state in DMSO and may have been resistant to
DMSO.
Figure 7
Fluorescence emission spectra of each RNase A in phosphate buffer
(0.05 mol/L, pH 6.5) and DMSO at 25 °C. (a) RNase A in (1) phosphate
buffer (0.05 mol/L, pH 6.5) and (2) DMSO. (b) CHRNase A in (1) phosphate
buffer (0.05 mol/L, pH 6.5) and (2) DMSO. RNase A and CHRNase A concentration:
0.5 mg/mL. Excitation wavelength: 280 nm.
Fluorescence emission spectra of each RNase A in phosphate buffer
(0.05 mol/L, pH 6.5) and DMSO at 25 °C. (a) RNase A in (1) phosphate
buffer (0.05 mol/L, pH 6.5) and (2) DMSO. (b) CHRNase A in (1) phosphate
buffer (0.05 mol/L, pH 6.5) and (2) DMSO. RNase A and CHRNase A concentration:
0.5 mg/mL. Excitation wavelength: 280 nm.
Conclusions
We succeeded in synthesizing
CHRNase A using CDI in DMSO. NMR measurements
suggested that cholesterol was conjugated to RNase A through the carbonyl
carbon (C=O) of CDI. Moreover, MALDI-TOF MS indicated that
one cholesteryl group was conjugated to RNase A.We conducted
a structural characterization of CHRNase A by examining
its folding state in a solid and in phosphate buffer (0.05 mol/L,
pH 6.5) , the secondary/tertiary structure, the environment around
aromatic residues, and the hydrophobicity on the protein surface.
DSC results suggested that CHRNase A was unfolded following the synthesis
process but folded in buffer solution. The CD spectra indicated that
the secondary structure of CHRNase A in buffer solution was similar
to that of RNase A. However, the helical content of CHRNase A was
less than that of RNase A, and the tertiary structure of CHRNase A
differed from RNase A. On the basis of fluorescence analysis excited
at 280 nm and CD spectra at 275 nm, we considered the cholesterol
was conjugated to a Tyr residue in RNase A. The conjugated cholesteryl
group is likely located on the protein surface according to the ANS
fluorescence assay and measurements of surface tension.Furthermore,
we measured the enzymatic activity of CHRNase A to
evaluate the effects of cholesterol conjugation on protein function.
The relative activity of CHRNase A to RNase A was 79 ± 7%, and
the Lineweaver–Burk plots implied that a decrease of the affinity
to cCMP had occurred. We then evaluated the enzyme activity of CHRNase
A before and after adding β-CyD and found that it increased
to approximately 129 ± 7% (estimated relative activity to RNase
A: approximately 100%); however, we observed no conformational change
in CHRNase A before and after adding β-CyD. Therefore, we assumed
that the enzyme activity of CHRNase A would be decreased by inhibition
by interaction with cholesteryl group and cCMP, which could be eliminated
by adding β-CyD, thus recovering enzyme activity. Additionally,
although RNase A was denatured in 100% DMSO, fluorescence measurements
indicated that the environment of Tyr residues in CHRNase A in 100%
DMSO was similar to that of native RNase A. Thus, CHRNase A may form
a folded state in DMSO and may be resistant to DMSO.This study
suggests that novel functions, including β-CyD-dependent
control of enzyme activity and improved endurance to organic solvents
like DMSO, can be added by cholesterol conjugation to RNase A. Such
changes in protein function may be more widely applicable. Hence,
we conclude that the techniques used in the present study have the
potential to enhance industrial and pharmaceutical methods, including
those used in the development of immobilized enzymes, allosteric enzymes,
biosensors, and protein formulations.
Experimental
Section
Materials
Bovine pancreatic RNase
A, cCMP, CHCA, SA, and ANS were purchased from Sigma-Aldrich (St.
Louis, USA). Cholesterol (Wako special grade), CDI (for organic synthesis),
DMSO (guaranteed reagent), dehydrated DMSO (for organic synthesis),
DMSO-d6 (for NMR), and acetone (guaranteed
reagent) were purchased from FUJIFILM Wako Pure Chemical Industries,
Ltd. (Osaka, Japan). β-CyD was purchased from Nihon Shokuhin
Kako Co., Ltd. (Tokyo, Japan). All other reagents were commercial
products of analytical grade. Phosphate buffer (0.05 mol/L, pH 6.5)
was prepared by Na2HPO4 and KH2PO4.
Synthesis of CHRNase A
CDI is used
for conjugation with many organic compounds and polymers such as polysaccharides,
peptides, and proteins.[69−74] The imidazole in CDI is highly reactive, which allows it to be converted
to an ester by reacting with alcohols or amines. Therefore, we used
the following procedure and synthesized CHRNase A by conjugating cholesterol
with hydroxyl and/or amino groups in RNase A.For conjugation
to RNase A, cholesterol was agitated with CDI in dehydrated DMSO at
50 °C for 3 h and cooled at room temperature (RT). Then, RNase
A was added based on the ratio mentioned here: CDI [mol]/RNase A [mol]
= 10 and cholesterol [mol]/RNase A [mol] = 12. This solution was agitated
at RT for 20 h to cause conjugation of the cholesteryl group to the
hydroxyl and amino groups of RNase A. CHRNase A powder was obtained
by first adding acetone, then washing with acetone several times,
and finally, drying under reduced pressure at RT. The product was
stored under −20 °C (Figure S7).
Confirmation of Cholesterol Conjugation to
RNase A and the Number of Conjugated Cholesteryl Groups
RNase A (15 mg)
and CHRNase A (15 mg) were separately dissolved in DMSO-d6 (0.7 mL). Following filtration of the solutions through
membrane filters (0.45 μm), they were analyzed using an NMR
spectrometer (JNM-LA500, JEOL, Tokyo, Japan). NMR (500 MHz 1H–, 125 MHz 13C–, and 1H–13C HMQC) spectra were all recorded at 25 °C. DMSO (2.49
ppm) was used as an internal standard in DMSO-d6.
Structural Characterization
of CHRNase A
Evaluation of Protein
State in a Solid State
and Buffer Solution Using DSC
In the solid state, RNase A
(5 mg), a physical mixture of RNase A and cholesterol (RNase A [mol]/cholesterol
[mol] = 1/12) (5 mg), and CHRNase A (5 mg) were separately placed
in aluminum sample pans, sealed, and analyzed by DSC (DSC8240D, Rigaku,
Tokyo, Japan). RNase A and CHRNase A were thawed and dried in a desiccator
before analyzing. The scan rate and scan range were set at 2 °C/min
and 40–160 °C, respectively; alumina (Al2O3) was used as a reference material, and the analysis was conducted
in air atmosphere.In the buffer solution, RNase A (30 mg/mL)
and CHRNase A (30 mg/mL) were separately prepared using phosphate
buffer (0.05 mol/L, pH 6.5). The solution (30 μL) was placed
in stainless steel sample pans and sealed for analysis by DSC (DSC8240D).
The scan rate and scan range were set at 2 °C/min and 40–100
°C, respectively. Phosphate buffer (0.05 mol/L, pH 6.5) was used
as a reference material, and the analysis was conducted in air atmosphere.
Evaluation of the Secondary and Tertiary
Structures by CD Spectroscopy
RNase A and CHRNase A were
separately dissolved in phosphate buffer (0.05 mol/L, pH 6.5) at a
concentration of 0.5 mg/mL and analyzed using a CD spectrometer (J-820,
JASCO, Tokyo, Japan). The CD spectra were recorded at 25 °C from
200 to 320 nm.To evaluate the environment around aromatic amino acids, RNase
A and CHRNase A were separately dissolved in a phosphate buffer (0.05
mol/L, pH 6.5) at a concentration of 0.5 mg/mL and analyzed using
a fluorescence spectrometer (FP-750, JASCO, Tokyo, Japan) with the
following parameters: excitation wavelength = 280 nm, band pass =
10 m, and emission band pass = 10 nm. Fluorescence emission spectra
were recorded at 25 °C from 260 to 400 nm.RNase A, CHRNase
A, and ANS were each dissolved in phosphate buffer (0.05 mol/L, pH
6.5) to evaluate the hydrophobic regions on the protein surface. Each
RNase A and ANS solution were mixed to achieve concentrations of 0.5
mg/mL and 1.0 × 10–4 mol/L, respectively, and
then analyzed using a fluorescence spectrometer with the following
parameters: excitation wavelength = 365 nm, band pass = 10 nm, and
emission band pass = 10 nm. Fluorescence emission spectra were recorded
at 25 °C from 400 to 600 nm.
Enzyme
Activity of CHRNase A
Relative Activity and
Enzyme Kinetic Constants
of CHRNase A
Relative Activity of
CHRNase A to RNase
A
RNase A and CHRNase A were separately dissolved in phosphate
buffer (0.05 mol/L, pH 6.5) to a concentration of 0.5 mg/mL (enzyme
solution). cCMP was dissolved in phosphate buffer (0.05 mol/L, pH
6.5) to a concentration of 0.1 mg/mL (substrate solution); 0.3 mL
of enzyme solution (3 h post-preparation) was added to 2.7 mL of the
substrate solution. The change in absorbance was analyzed using a
UV spectrometer (V-560, JASCO) for 10 s at 286 nm at 25 °C. The
relative activity of CHRNase A was calculated by the following formula
Enzyme
Kinetic Constants of CHRNase A
RNase A and CHRNase A were
prepared similarly as for measuring
the relative activity, but the cCMP substrate solution was formulated
to have a concentration range of 0.02–0.1 mg/mL. Enzyme solution
(0.3 mL, 3 h post-preparation) was added to 2.7 mL of the substrate
solution, and the change in absorbance was recorded as for the relative
activity at 286 nm. The initial reaction rate for each RNase A was
computed using the initial slope. Using a Lineweaver–Burk plot,
the Michaelis constant (Km) and the maximum
rate (Vmax) for each RNase A were calculated.
Effect of the Addition of β-CyD on
the Enzyme Activity of CHRNase A
CHRNase A was dissolved
in phosphate buffer (0.05 mol/L, pH 6.5) to achieve a concentration
of 0.5 mg/mL (CHRNase A solution without β-CyD). β-CyD
was dissolved in phosphate buffer (0.05 mol/L, pH 6.5) to a concentration
of 0.2 × 10–3 mol/L; 0.1 mL of 0.2 × 10–3 mol/L β-CyD or the phosphate buffer (0.05 mol/L,
pH 6.5) was added to 3.0 mL of CHRNase A solution (CHRNase A solution
with or without β-CyD). cCMP was freshly dissolved in phosphate
buffer (0.05 mol/L, pH 6.5) to achieve a concentration of 0.1 mg/mL
in each measurement (substrate solution); 0.3 mL of CHRNase A solution
after 24 h post-preparation was added to 2.7 mL of the substrate solution.
The change in absorbance was analyzed using a UV spectrometer for
10 s at 286 nm at 25 °C. The relative activity of CHRNase A before
and after the addition of β-CyD was calculated using the following
formula
Evaluation
of the Environment of Tyrosine
Residues to DMSO
RNase A and CHRNase A were separately dissolved
in DMSO at a concentration of 0.5 mg/mL. The solutions were analyzed
using a fluorescence spectrometer with the following parameters: excitation
wavelength = 280 nm, band pass = 10 nm, and emission band pass = 10
nm. Fluorescence emission spectra were recorded at 25 °C from
260 to 400 nm.
Authors: Antonietta M Lillo; Ciana L Lopez; Trideep Rajale; Hung-Ju Yen; Harsha D Magurudeniya; M Lisa Phipps; Eva Rose M Balog; Timothy C Sanchez; Srinivas Iyer; Hsing-Lin Wang; Ryszard Michalczyk; Reginaldo C Rocha; Jennifer S Martinez Journal: Bioconjug Chem Date: 2018-07-19 Impact factor: 4.774
Authors: Mohamed Gaber; Mostafa T Mabrouk; May S Freag; Sachin K Khiste; Jia-You Fang; Kadria A Elkhodairy; Ahmed O Elzoghby Journal: Eur J Pharm Biopharm Date: 2018-10-06 Impact factor: 5.571
Authors: Michael E Østergaard; Michaela Jackson; Audrey Low; Alfred E Chappell; Richard G Lee; Rachel Q Peralta; Jinghua Yu; Garth A Kinberger; Amy Dan; Rick Carty; Michael Tanowitz; Patrick Anderson; Tae-Won Kim; Linda Fradkin; Adam E Mullick; Sue Murray; Frank Rigo; Thazha P Prakash; C Frank Bennett; Eric E Swayze; Hans J Gaus; Punit P Seth Journal: Nucleic Acids Res Date: 2019-07-09 Impact factor: 16.971